ADORA2A and neoplasm: The A2A adenosine receptor agonist regadenoson (Lexiscan), administered at a dose of 0.0005 mg/kg, has been shown to enhance BBB permeability—permitting the passage of 70 kDa dextran in murine and rat models [136], facilitating T cell transmigration across a human in vitro BBB model [137], and increasing brain concentrations of TMZ by 60% in non-tumor-bearing rats [139].